TD Cowen Maintains Tectonic Therapeutic(TECX.US) With Buy Rating
Piper Sandler Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $76
Piper Sandler Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $76
TD Cowen Maintains Tectonic Therapeutic(TECX.US) With Buy Rating
Piper Sandler Sticks to Their Buy Rating for Tectonic Therapeutic (TECX)
Wells Fargo Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $55
Tectonic Therapeutic Analyst Ratings
Wells Fargo Initiates Tectonic Therapeutic at Overweight With $55 Price Target
Wells Fargo Initiates Tectonic Therapeutic(TECX.US) With Buy Rating, Announces Target Price $55
Leerink Partners Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Announces Target Price $49
TD Cowen Maintains Tectonic Therapeutic(TECX.US) With Buy Rating
Leerink Partners Remains a Buy on Tectonic Therapeutic (TECX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY), PTC Therapeutics (PTCT) and Tectonic Therapeutic (TECX)
Tectonic Therapeutic Price Target Announced at $49.00/Share by Leerink Partners
Tectonic Therapeutic Analyst Ratings
Leerink Partners Initiates Tectonic Therapeutic(TECX.US) With Buy Rating, Announces Target Price $49
Tectonic Therapeutic Analyst Ratings
Tectonic Therapeutic Analyst Ratings
AVROBIO's Strategic Ambiguity: A Commitment to Analysis With Uncertain Outcomes for Shareholders
Avrobio (AVRO) Gets a Buy From Wells Fargo
No Data
No Data